Coherus Oncology Inc [CHRS] stock prices are up 29.56% to $2.06 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CHRS shares have gain 24.10% over the last week, with a monthly amount glided 47.14%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Coherus Oncology Inc [NASDAQ: CHRS] stock has seen the most recent analyst activity on January 23, 2026, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $10. Previously, Maxim Group upgraded its rating to Buy on September 04, 2025. On August 16, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $1.50 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $11 on November 17, 2023. Maxim Group downgraded its rating to a Hold. Citigroup started tracking with a Buy rating for this stock on July 24, 2023, and assigned it a price target of $12. In a note dated May 01, 2023, Truist initiated an Buy rating and provided a target price of $24 on this stock.
The stock price of Coherus Oncology Inc [CHRS] has been fluctuating between $0.71 and $1.89 over the past year. Currently, Wall Street analysts expect the stock to reach $6.02 within the next 12 months. Coherus Oncology Inc [NASDAQ: CHRS] shares were valued at $2.06 at the most recent close of the market. An investor can expect a potential return of 192.23% based on the average CHRS price forecast.
Analyzing the CHRS fundamentals
The Coherus Oncology Inc [NASDAQ:CHRS] reported sales of 83.57M for trailing twelve months, representing a drop of -83.65%. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -2.12%, Pretax Profit Margin comes in at -2.24%, and Net Profit Margin reading is 1.85%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is -5.75 and Total Capital is -1.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Coherus Oncology Inc [NASDAQ:CHRS]’s Current Ratio is 1.24. As well, the Quick Ratio is 1.23, while the Cash Ratio is 0.28. Considering the valuation of this stock, the price to sales ratio is 2.98, the price to book ratio is 2.73.
Transactions by insiders
Recent insider trading involved Wahlstrom Mats, Director, that happened on May 23 ’25 when 99988.0 shares were sold.
